Safety and Tolerability of CHR-2845 to Treat Haematological Diseases or Lymphoid Malignancies

NCT00820508 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Hematological Disease
Lymphoid Malignancies

Interventions

DRUG: CHR-2845

Sponsor

Chroma Therapeutics